nach oben

Translational Stroke Research

Erschienen in:

01.04.2014 | Review Article

Current Management of Delayed Cerebral Ischemia: Update from Results of Recent Clinical Trials

verfasst von: Shakira Brathwaite, R. Loch Macdonald

Erschienen in: Translational Stroke Research | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Subarachnoid hemorrhage (SAH) accounts for 5–7 % of all strokes worldwide and is associated with high mortality and morbidity. Even after surgical intervention, approximately 30 % of patients develop long-term cognitive and neurological deficits that significantly affect their capacity to return to work or daily life unassisted. Much of this stems from a secondary ischemic phenomenon referred to as delayed cerebral ischemia (DCI). While DCI has been historically attributed to the narrowing of the large basal cerebral arteries, it is now recognized that numerous pathways contribute to its pathogenesis, including microcirculatory dysfunction, microthrombosis, cortical spreading depression, and early brain injury. This paper seeks to summarize some of the key pathophysiological events that are associated with poor outcome after SAH, provide a general overview of current methods of treating SAH patients, and review the results of recent clinical trials directed at improving outcome after SAH. The scientific basis of these studies will be discussed, in addition to the available results and recommendations for effective patient management. Therapeutic methods under current clinical investigation will also be addressed. In particular, the mechanisms by which they are expected to elicit improved outcome will be investigated, as well as the specific study designs and anticipated time lines for completion.

Al-Khindi T, Macdonald RL, Schweizer TA. Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke. 2010;41:e519–36.PubMed

Al-Tamimi YZ et al. A review of delayed ischemic neurologic deficit following aneurysmal subarachnoid hemorrhage: historical overview, current treatment, and pathophysiology. World Neurosurg. 2010;73:654–67.PubMed

Amin-Hanjani S, Ogilvy CS, Barker 2nd FG. Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis. Neurosurgery. 2004;54:326–34. discussion 334-5.PubMed

Barth M et al. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: a prospective, randomized, double-blind phase IIa study. Stroke. 2007;38:330–6.PubMed

Bavbek M et al. Monoclonal antibodies against ICAM-1 and CD18 attenuate cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. Stroke. 1998;29:1930–5. discussion 1935-6.PubMed

Brandt L et al. Vasoconstrictive effects of human post-hemorrhagic cerebrospinal fluid on cat pial arterioles in situ. J Neurosurg. 1981;54:351–6.PubMed

Breder CD et al. Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system. J Comp Neurol. 1993;337:543–67.PubMed

Cahill J, Calvert JW, Zhang JH. Mechanisms of early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2006;26:1341–53.PubMed

Chow M, Dumont AS, Kassell NF. Endothelin receptor antagonists and cerebral vasospasm: an update. Neurosurgery. 2002;51:1333–41. discussion 1342.PubMed

10.

Chung IY, Benveniste EN. Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. J Immunol. 1990;144:2999–3007.PubMed

11.

Chwajol M et al. Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage. Neurocrit Care. 2008;8:418–26.PubMed

12.

Chyatte D et al. Inflammation and intracranial aneurysms. Neurosurgery. 1999;45:1137–46. discussion 1146-7.PubMed

13.

Connolly Jr ES et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:1711–37.PubMed

14.

Contermans J et al. A comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients. Br J Clin Pharmacol. 1995;39:135–41.PubMedCentralPubMed

15.

Crowley RW et al. Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage. Stroke. 2011;42:919–23.PubMed

16.

Dankbaar JW et al. Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review. Crit Care. 2010;14:R23.PubMedCentralPubMed

17.

Dankbaar JW et al. Changes in cerebral perfusion around the time of delayed cerebral ischemia in subarachnoid hemorrhage patients. Cerebrovasc Dis. 2011;32:133–40.PubMed

18.

de Rooij NK et al. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007;78:1365–72.PubMedCentralPubMed

19.

Dejam A et al. Nitrite infusion in humans and nonhuman primates: endocrine effects, pharmacokinetics, and tolerance formation. Circulation. 2007;116:1821–31.PubMed

20.

Dhar R, Diringer MN. The burden of the systemic inflammatory response predicts vasospasm and outcome after subarachnoid hemorrhage. Neurocrit Care. 2008;8:404–12.PubMedCentralPubMed

21.

Diringer MN et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15:211–40.PubMed

22.

Dorhout Mees SM, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007a; CD000277

23.

Dorhout Mees SM, et al. Antiplatelet therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007b; CD006184

24.

Dorhout Mees SM et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet. 2012;380:44–9.PubMed

25.

Dorsch NW, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage, part I: incidence and effects. J Clin Neurosci. 1994;1:19–26.PubMed

26.

Dorsch NW. Cerebral arterial spasm—a clinical review. Br J Neurosurg. 1995;9:403–12.PubMed

27.

Dreier JP et al. Nitric oxide scavenging by hemoglobin or nitric oxide synthase inhibition by N-nitro-l-arginine induces cortical spreading ischemia when K+ is increased in the subarachnoid space. J Cereb Blood Flow Metab. 1998;18:978–90.PubMed

28.

Dreier JP et al. Products of hemolysis in the subarachnoid space inducing spreading ischemia in the cortex and focal necrosis in rats: a model for delayed ischemic neurological deficits after subarachnoid hemorrhage? J Neurosurg. 2000;93:658–66.PubMed

29.

Dreier JP et al. Ischemia triggered by red blood cell products in the subarachnoid space is inhibited by nimodipine administration or moderate volume expansion/hemodilution in rats. Neurosurgery. 2002;51:1457–65. discussion 1465-7.PubMed

30.

Dreier JP et al. Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations. Brain. 2006;129:3224–37.PubMed

31.

Dreier JP et al. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain. 2009;132:1866–81.PubMedCentralPubMed

32.

Dreier JP. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med. 2011;17:439–47.PubMed

33.

Fabry Z et al. Production of the cytokines interleukin 1 and 6 by murine brain microvessel endothelium and smooth muscle pericytes. J Neuroimmunol. 1993;47:23–34.PubMed

34.

Fassbender K et al. Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry. 2001;70:534–7.PubMedCentralPubMed

35.

Fathi AR et al. Reversal of cerebral vasospasm via intravenous sodium nitrite after subarachnoid hemorrhage in primates. J Neurosurg. 2011;115:1213–20.PubMed

36.

Feigin VL et al. Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review. Neurology. 1998;50:876–83.PubMed

37.

Feigin VL et al. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009;8:355–69.PubMed

38.

Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6:1–9.PubMed

39.

Friedrich B et al. Experimental subarachnoid hemorrhage causes early and long-lasting microarterial constriction and microthrombosis: an in-vivo microscopy study. J Cereb Blood Flow Metab. 2012;32:447–55.PubMedCentralPubMed

40.

Friedrich V et al. Reduction of neutrophil activity decreases early microvascular injury after subarachnoid haemorrhage. J Neuroinflammation. 2011;8:103.PubMedCentralPubMed

41.

Fujii Y et al. Serial changes of hemostasis in aneurysmal subarachnoid hemorrhage with special reference to delayed ischemic neurological deficits. J Neurosurg. 1997;86:594–602.PubMed

42.

Gaetani P et al. Cisternal CSF levels of cytokines after subarachnoid hemorrhage. Neurol Res. 1998;20:337–42.PubMed

43.

Gomis P et al. Randomized, double-blind, placebo-controlled, pilot trial of high-dose methylprednisolone in aneurysmal subarachnoid hemorrhage. J Neurosurg. 2010;112:681–8.PubMed

44.

Grasso G et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci U S A. 2002;99:5627–31.PubMedCentralPubMed

45.

Grubb Jr RL et al. Effects of subarachnoid hemorrhage on cerebral blood volume, blood flow, and oxygen utilization in humans. J Neurosurg. 1977;46:446–53.PubMed

46.

Hallenbeck JM et al. Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. Stroke. 1986;17:246–53.PubMed

47.

Herz DA, Baez S, Shulman K. Pial microcirculation in subarachnoid hemorrhage. Stroke. 1975;6:417–24.PubMed

48.

Hirashima Y et al. Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage. Neurochem Res. 1997;22:1249–55.PubMed

49.

Hirashima Y et al. Cerebrospinal fluid tissue factor and thrombin–antithrombin III complex as indicators of tissue injury after subarachnoid hemorrhage. Stroke. 1997;28:1666–70.PubMed

50.

Ishikawa M et al. Platelet and leukocyte adhesion in the microvasculature at the cerebral surface immediately after subarachnoid hemorrhage. Neurosurgery. 2009;64:546–53. discussion 553–4.PubMed

51.

Johnston SC, Selvin S, Gress DR. The burden, trends, and demographics of mortality from subarachnoid hemorrhage. Neurology. 1998;50:1413–8.PubMed

52.

Juvela S, Hillbom M, Kaste M. Platelet thromboxane release and delayed cerebral ischemia in patients with subarachnoid hemorrhage. J Neurosurg. 1991;74:386–92.PubMed

53.

Juvela S, Porras M, Poussa K. Natural history of unruptured intracranial aneurysms: probability of and risk factors for aneurysm rupture. J Neurosurg. 2000;93:379–87.PubMed

54.

Kasuya H, Shimizu T. Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid hemorrhage. J Neurosurg. 1989;71:741–6.PubMed

55.

Kasuya H, Shimizu T, Takakura K. Thrombin activity in CSF after SAH is correlated with the degree of SAH the persistence of subarachnoid clot and the development of vasospasm. Acta Neurochir (Wien). 1998;140:579–84.

56.

Keep RF et al. Ischemia-induced endothelial cell dysfunction. Acta Neurochir Suppl. 2005;95:399–402.PubMed

57.

Killeen RP et al. Comparison of CT perfusion and digital subtraction angiography in the evaluation of delayed cerebral ischemia. Acad Radiol. 2011;18:1094–100.PubMedCentralPubMed

58.

Klimo Jr P et al. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg. 2004;100:215–24.PubMed

59.

Kramer AH et al. Statin use was not associated with less vasospasm or improved outcome after subarachnoid hemorrhage. Neurosurgery. 2008;62:422–7. discussion 427–30.PubMed

60.

Kramer AH, Fletcher JJ. Locally-administered intrathecal thrombolytics following aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurocrit Care. 2011;14:489–99.PubMed

61.

Kubo Y et al. Serum inflammatory adhesion molecules and high-sensitivity C-reactive protein correlates with delayed ischemic neurologic deficits after subarachnoid hemorrhage. Surg Neurol. 2008;69:592–6. discussion 596.PubMed

62.

Kusaka G et al. Signaling pathways for early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2004;24:916–25.PubMed

63.

Kwon KY, Jeon BC. Cytokine levels in cerebrospinal fluid and delayed ischemic deficits in patients with aneurysmal subarachnoid hemorrhage. J Korean Med Sci. 2001;16:774–80.PubMedCentralPubMed

64.

Kwon OY et al. The utility and benefits of external lumbar CSF drainage after endovascular coiling on aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2008;43:281–7.PubMedCentralPubMed

65.

Leao A. Spreading depression of activity in the cerebral cortex. J Neurophysiol. 1944;7:359–90.

66.

Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118.PubMedCentralPubMed

67.

Liu GJ et al. Meta-analysis of the effectiveness and safety of prophylactic use of nimodipine in patients with an aneurysmal subarachnoid haemorrhage. CNS Neurol Disord Drug Targets. 2011;10:834–44.PubMed

68.

Liu GJ et al. Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. Eur J Clin Pharmacol. 2012;68:131–9.PubMed

69.

Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: population-based study and systematic review. Neurology. 2010;74:1494–501.PubMedCentralPubMed

70.

Lu D et al. Delayed thrombosis after traumatic brain injury in rats. J Neurotrauma. 2004;21:1756–66.PubMed

71.

Lutjohann D et al. High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. Steroids. 2004;69:431–8.PubMed

72.

Ma L et al. Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials. Brain Inj. 2010;24:730–5.PubMed

73.

Macdonald RL, Weir BK. Cerebral vasospasm and free radicals. Free Radic Biol Med. 1994;16:633–43.PubMed

74.

MacDonald RL. Evidence-based treatment of subarachnoid hemorrhage: current status and future possibilities. Clin Neurosurg. 2006;53:257–66.PubMed

75.

Macdonald RL, Pluta RM, Zhang JH. Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol. 2007;3:256–63.PubMed

76.

Macdonald RL et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (Conscious-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39:3015–21.PubMed

77.

Macdonald RL et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (Conscious-2). Lancet Neurol. 2011;10:618–25.PubMed

78.

Mack WJ et al. Outcome prediction with serum intercellular adhesion molecule-1 levels after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2002;96:71–5.PubMed

79.

Mack WJ et al. Early plasma complement C3a levels correlate with functional outcome after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2007;61:255–60. discussion 260–1.PubMed

80.

Manno EM et al. The safety and efficacy of cyclosporine A in the prevention of vasospasm in patients with Fisher grade 3 subarachnoid hemorrhages: a pilot study. Neurosurgery. 1997;40:289–93.PubMed

81.

Matsuno A et al. Severe subarachnoid hemorrhage during transsphenoidal surgery for pituitary adenoma. Surg Neurol. 1993;39:276–8.PubMed

82.

Mies G, Paschen W. Regional changes of blood flow, glucose, and ATP content determined on brain sections during a single passage of spreading depression in rat brain cortex. Exp Neurol. 1984;84:249–58.PubMed

83.

Morganti-Kossmann MC et al. Autocrine and paracrine regulation of astrocyte function by transforming growth factor-beta. J Neuroimmunol. 1992;39:163–73.PubMed

84.

Muench E et al. Effects of hypervolemia and hypertension on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation after subarachnoid hemorrhage. Crit Care Med. 2007;35:1844–51. quiz 1852.PubMed

85.

Muroi C et al. Magnesium sulfate in the management of patients with aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, dose-adapted trial. Surg Neurol. 2008;69:33–9. discussion 39.PubMed

86.

Neil-Dwyer G et al. Delayed cerebral ischaemia: the pathological substrate. Acta Neurochir (Wien). 1994;131:137–45.

87.

Nina P et al. A study of blood coagulation and fibrinolytic system in spontaneous subarachnoid hemorrhage. Correlation with Hunt–Hess grade and outcome. Surg Neurol. 2001;55:197–203.PubMed

88.

Nornes H, Magnaes B. Intracranial pressure in patients with ruptured saccular aneurysm. J Neurosurg. 1972;36:537–47.PubMed

89.

Nystoriak MA et al. Fundamental increase in pressure-dependent constriction of brain parenchymal arterioles from subarachnoid hemorrhage model rats due to membrane depolarization. Am J Physiol Heart Circ Physiol. 2011;300:H803–12.PubMedCentralPubMed

90.

Ohkuma H et al. Morphological changes of intraparenchymal arterioles after experimental subarachnoid hemorrhage in dogs. Neurosurgery. 1997;41:230–5. discussion 235–6.PubMed

91.

Ohkuma H et al. Impact of cerebral microcirculatory changes on cerebral blood flow during cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2000;31:1621–7.PubMed

92.

Oldfield EH, et al. Safety and pharmacokinetics of sodium nitrite in patients with subarachnoid hemorrhage: a Phase IIA study. J Neurosurg 2013

93.

Omeis I et al. Treatment of cerebral vasospasm with biocompatible controlled-release systems for intracranial drug delivery. Neurosurgery. 2008;63:1011–9. discussion 1019–21.PubMed

94.

Parra A et al. Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: a matched controlled cohort study. Neurosurgery. 2005;56:476–84. discussion 476–84.PubMed

95.

Passier PE et al. Life satisfaction and return to work after aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2011;20:324–9.PubMed

96.

Pellettieri L et al. Serum immunocomplexes in patients with subarachnoid hemorrhage. Neurosurgery. 1986;19:767–71.PubMed

97.

Peltonen S et al. Hemostasis and fibrinolysis activation after subarachnoid hemorrhage. J Neurosurg. 1997;87:207–14.PubMed

98.

Pennings FA, Bouma GJ, Ince C. Direct observation of the human cerebral microcirculation during aneurysm surgery reveals increased arteriolar contractility. Stroke. 2004;35:1284–8.PubMed

99.

Perkins E et al. Evaluation of the microvasculature and cerebral ischemia after experimental subarachnoid hemorrhage in dogs. J Neurosurg. 2002;97:896–904.PubMed

100.

Peterson JW et al. The role of inflammation in experimental cerebral vasospasm. J Neurosurg. 1990;72:767–74.PubMed

101.

Petruk KC et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988;68:505–17.PubMed

102.

Pisapia JM et al. Microthrombosis after experimental subarachnoid hemorrhage: time course and effect of red blood cell-bound thrombin-activated pro-urokinase and clazosentan. Exp Neurol. 2012;233:357–63.PubMed

103.

Pluta RM et al. Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA. 2005;293:1477–84.PubMed

104.

Pluta RM et al. Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought. Neurol Res. 2009;31:151–8.PubMedCentralPubMed

105.

Pradilla G et al. Systemic L-citrulline prevents cerebral vasospasm in haptoglobin 2-2 transgenic mice after subarachnoid hemorrhage. Neurosurgery. 2012;70:747–56. discussion 756-7.PubMed

106.

Prunell GF et al. Inflammation in the brain after experimental subarachnoid hemorrhage. Neurosurgery. 2005;56:1082–92. discussion 1082–92.PubMed

107.

Pyne-Geithman GJ et al. Role of bilirubin oxidation products in the pathophysiology of DIND following SAH. Acta Neurochir Suppl. 2013;115:267–73.PubMed

108.

Raabe A et al. Relative importance of hypertension compared with hypervolemia for increasing cerebral oxygenation in patients with cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg. 2005;103:974–81.PubMed

109.

Reilly C et al. Clot volume and clearance rate as independent predictors of vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2004;101:255–61.PubMed

110.

Romano JG et al. Detection of microemboli by transcranial Doppler ultrasonography in aneurysmal subarachnoid hemorrhage. Neurosurgery. 2002;50:1026–30. discussion 1030–1.PubMed

111.

Roos YB et al. Nimodipine increases fibrinolytic activity in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2001;32:1860–2.PubMed

112.

Rothoerl RD et al. ICAM-1 and VCAM-1 expression following aneurysmal subarachnoid hemorrhage and their possible role in the pathophysiology of subsequent ischemic deficits. Cerebrovasc Dis. 2006;22:143–9.PubMed

113.

Ryba M et al. Cyclosporine A prevents neurological deterioration of patients with SAH—a preliminary report. Acta Neurochir (Wien). 1991;112:25–7.

114.

Sehba FA, Pluta RM, Zhang JH. Metamorphosis of subarachnoid hemorrhage research: from delayed vasospasm to early brain injury. Mol Neurobiol. 2011;43:27–40.PubMedCentralPubMed

115.

Senbokuya N et al. Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial. J Neurosurg. 2013;118:121–30.PubMed

116.

Somjen GG. Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. Physiol Rev. 2001;81:1065–96.PubMed

117.

Springborg JB et al. A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in rats. Br J Pharmacol. 2002;135:823–9.PubMedCentralPubMed

118.

Springborg JB et al. Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir (Wien). 2007;149:1089–101. discussion 1101.

119.

Starke, R.M., Connolly, E.S., Jr., Participants in the International Multi-Disciplinary Consensus Conference on the Critical Care Management of Subarachnoid, H. Rebleeding after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2011;15:241–6.

120.

Stein SC et al. Thromboembolism and delayed cerebral ischemia after subarachnoid hemorrhage: an autopsy study. Neurosurgery. 2006;59:781–7. discussion 787-8.PubMed

121.

Suarez JI, Martin RH. Treatment of subarachnoid hemorrhage with human albumin: ALISAH study. Rationale and design. Neurocrit Care. 2010;13:263–77.PubMed

122.

Suarez JI et al. The Albumin in Subarachnoid Hemorrhage (ALISAH) multicenter pilot clinical trial: safety and neurologic outcomes. Stroke. 2012;43:683–90.PubMedCentralPubMed

123.

Suzuki S et al. Cerebral microthrombosis in symptomatic cerebral vasospasm—a quantitative histological study in autopsy cases. Neurol Med Chir (Tokyo). 1990;30:309–16.

124.

Suzuki Y et al. Safety and efficacy of fasudil monotherapy and fasudil–ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo). 2008;48:241–7. discussion 247–8.

125.

Tam AK et al. Impact of systemic inflammatory response syndrome on vasospasm, cerebral infarction, and outcome after subarachnoid hemorrhage: exploratory analysis of CONSCIOUS-1 database. Neurocrit Care. 2010;13:182–9.PubMed

126.

Thai QA, Oshiro EM, Tamargo RJ. Inhibition of experimental vasospasm in rats with the periadventitial administration of ibuprofen using controlled-release polymers. Stroke. 1999;30:140–7.PubMed

127.

Trojanowski T. Early effects of experimental arterial subarachnoid haemorrhage on the cerebral circulation. Part I: Experimental subarachnoid haemorrhage in cat and its pathophysiological effects. Methods of regional cerebral blood flow measurement and evaluation of microcirculation. Acta Neurochir (Wien). 1984;72:79–94.

128.

Tsai PT et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci. 2006;26:1269–74.PubMed

129.

Tseng MY et al. Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg. 2009;111:171–80.PubMed

130.

Tseng MY, Participants in the International Multidisciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Summary of evidence on immediate statins therapy following aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2011;15:298–301.PubMed

131.

Uhl E et al. Intraoperative detection of early microvasospasm in patients with subarachnoid hemorrhage by using orthogonal polarization spectral imaging. Neurosurgery. 2003;52:1307–15. disacussion 1315–7.PubMed

132.

van den Bergh WM et al. Hypomagnesemia after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2003;52:276–81. discussion 281–2.PubMed

133.

van den Bergh WM et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2005;36:1011–5.PubMed

134.

van den Bergh WM et al. Randomized controlled trial of acetylsalicylic acid in aneurysmal subarachnoid hemorrhage: the MASH Study. Stroke. 2006;37:2326–30.PubMed

135.

van Gijn J, Rinkel GJ. Subarachnoid haemorrhage: diagnosis, causes and management. Brain. 2001;124:249–78.PubMed

136.

Vergouwen MD et al. Dihydropyridine calcium antagonists increase fibrinolytic activity: a systematic review. J Cereb Blood Flow Metab. 2007;27:1293–308.PubMed

137.

Vergouwen MD et al. Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke. 2010;41:e47–52.PubMed

138.

Vergouwen MD et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41:2391–5.PubMed

139.

Vergouwen MD, Algra A, Rinkel GJ. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke. 2012;43:2671–6.PubMed

140.

Vollmer DG, Takayasu M, Dacey Jr RG. An in vitro comparative study of conducting vessels and penetrating arterioles after experimental subarachnoid hemorrhage in the rabbit. J Neurosurg. 1992;77:113–9.PubMed

141.

Wan H, Loch Macdonald R. Circulatory and vascular changes after aneurysmal subarachnoid hemorrhage. J Neurosurg Sci. 2011;55:329–41.PubMed

142.

Wang Z et al. Influence of simvastatin on microthrombosis in the brain after subarachnoid hemorrhage in rats: a preliminary study. Ann Clin Lab Sci. 2010;40:32–42.PubMed

143.

Wilkins RH. Cerebral vasospasm. Crit Rev Neurobiol. 1990;6:51–77.PubMed

144.

Woitzik J et al. Delayed cerebral ischemia and spreading depolarization in absence of angiographic vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2012;32:203–12.PubMedCentralPubMed

145.

Wong GK et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke. 2010;41:921–6.PubMed

146.

Xi G et al. Role of blood clot formation on early edema development after experimental intracerebral hemorrhage. Stroke. 1998;29:2580–6.PubMed

147.

Yanamoto H et al. Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage. Neurosurgery. 1992;30:358–63.PubMed

148.

Yuan J. Neuroprotective strategies targeting apoptotic and necrotic cell death for stroke. Apoptosis. 2009;14:469–77.PubMedCentralPubMed

149.

Zabramski JM, Spetzler RF, Bonstelle C. Chronic cerebral vasospasm: effect of volume and timing of hemorrhage in a canine model. Neurosurgery. 1986;18:1–6.PubMed

150.

Zhao XD et al. A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate. J Clin Neurosci. 2009;16:1394–7.PubMed

151.

Zubkov YN, Nikiforov BM, Shustin VA. Balloon catheter technique for dilatation of constricted cerebral arteries after aneurysmal SAH. Acta Neurochir (Wien). 1984;70:65–79.

152.

Zwienenberg-Lee M et al. Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial. Stroke. 2008;39:1759–65.PubMed

Titel: Current Management of Delayed Cerebral Ischemia: Update from Results of Recent Clinical Trials
verfasst von: Shakira Brathwaite
R. Loch Macdonald
Publikationsdatum: 01.04.2014
Verlag: Springer US
Erschienen in: Translational Stroke Research / Ausgabe 2/2014
Print ISSN: 1868-4483
Elektronische ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-013-0316-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Current Management of Delayed Cerebral Ischemia: Update from Results of Recent Clinical Trials

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Tenascin-C Causes Neuronal Apoptosis After Subarachnoid Hemorrhage in Rats

Early MoCA-Assessed Cognitive Impairment After Aneurysmal Subarachnoid Hemorrhage and Relationship to 1-Year Functional Outcome

Subarachnoid Hemorrhage: a Review of Experimental Studies on the Microcirculation and the Neurovascular Unit

Endovascular Management of Cerebral Aneurysm

Intracisternal Administration of Tissue Plasminogen Activator Improves Cerebrospinal Fluid Flow and Cortical Perfusion After Subarachnoid Hemorrhage in Mice

Vascular Neural Network: the Importance of Vein Drainage in Stroke

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie